Shares of Altimmune are trading higher after a NYPost article highlighted a study comparing the company's Pemvidutide to Ozempic.
Portfolio Pulse from Benzinga Newsdesk
Shares of Altimmune are trading higher following a NYPost article that highlighted a study comparing the company's Pemvidutide to Ozempic.
June 27, 2024 | 2:34 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Altimmune shares are trading higher after a NYPost article highlighted a study comparing the company's Pemvidutide to Ozempic.
The positive comparison of Pemvidutide to a well-known drug like Ozempic is likely to boost investor confidence in Altimmune's product pipeline, driving the stock price higher in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100